Angiotensin-converting enzyme (ACE) inhibitors reduce systemic and coronary vasoconstriction by modulating sympathetic neuroeffector function and by decreasing sympathetic activation. Here, blood pressure, and tissue concentrations of noradrenaline and neuropeptide Y (NPY) were studied in normotensive and spontaneously hypertensive rats (SHR) after 2 weeks treatment with lisinopril (0.3 mg/day; osmotic mini-pump). MAP was reduced in both normotensive rats and SHR after lisinopril by 32 mm Hg and 66 mm Hg respectively (P Ͻ 0.001 compared to corresponding control rats). NPY levels were significantly higher in extracts of atria, kidney,
Introduction
The sympathetic nervous system and the reninangiotensin system (RAS) play key roles in the regulation of vasomotor tone. Their relative contributions to changes in vascular resistance during hypertension and in the development of heart failure have yet to be fully defined. Inhibitors of angiotensin-converting enzyme (ACE) lower blood pressure (BP) in human essential hypertension, even though circulating renin levels are normal or slightly reduced. 1 However, the presence of components of RAS in the vascular wall is widely accepted as evidence for a key local role for AII in modulating sympathetic function and vascular tone. [2] [3] [4] The success of chronic ACE inhibition as a treatment for hypertension is linked to the degree of inhibition of vascular ACE, resulting in reduced local effects of AII on vascular smooth muscle cells and inhibition of the facilitatory actions of AII on noradrenaline release and neurogenic vasoconstrictor responses. [3] [4] [5] Demonstrating this interplay between vascular ACE and the sympathetic nervous system has been difficult because of the lack of sensitive markers.
spleen and adrenal of normotensive rats compared to SHR. Lisinopril treatment increased NPY levels in atria and skeletal muscle extracts of SHR by 15% and 70% respectively (P Ͻ 0.05). Lisinopril also significantly increased noradrenaline content of the atria by 16% in SHR (P Ͻ 0.05). The decrease in MAP and increase in tissue levels of sympathetic neurotransmitters provide further evidence that inhibition of ACE decreases sympathetic neurotransmission leading to accumulation of stored neurotransmitters.
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The widespread co-existence of neuropeptide Y (NPY) with noradrenaline (NA) in perivascular nerve fibres provides a morphological basis for the direct vasoconstrictor actions of NPY and its ability to sensitize vascular smooth muscle to NA induced contractions. 7 Despite evidence for NPY and NA acting as co-transmitters in the control of vascular resistance, 8 it is not known whether factors exerting a regulatory influence on sympathetic function alter the synthesis and release of these neurotransmitters in a differential or parallel manner. Here the effect of ACE inhibition with lisinopril on tissue levels of NPY and NA were studied in normotensive and spontaneously hypertensive rats (SHR).
Materials and methods
Ten-week old normotensive Wistar rats (n = 24, 237 ± 1 g) and spontaneously hypertensive rats from the Kyoto strain (SHR; n = 24, 225 ± 1 g) were obtained from KFM (4414 Fullinsdorf, Switzerland). Rats of each strain were divided into three groups: lisinopril-minipump (n = 8), saline-minipump (n = 7), and untreated controls (n = 9). Rats receiving minipumptreatment were anaesthetised by i.p. injection with ketamine (100 mg/kg, Parke-Davis) and midazolam (5 mg/kg, Hoffman-La-Roche, Basel, Switzerland), and osmotic minipumps (model 2002, 14 day function 0.5 l/h; Alzet Corp, Palo Alto, CA, USA) containing either lisinopril (25 mg/ml) or sterile 0.9% saline were inserted intra-peritoneally via a midline
Journal of Human Hypertension incision. Based on the pump delivery rate this corresponds to a daily dose of 0.3 mg (Ϸ1 to 1.3 mg/kg/day). Given orally this dose is effective in lowering blood pressure in normal rats. 9 Two weeks after implantation of minipumps rats were anaesthetised by i.p. injection of ketamine and midazolam, as above, and polypropylene cannulae were inserted into the right femoral artery for measuring BP, and right femoral vein for infusing a maintenance dose of anaesthetic (0.8 mg/kg/min ketamine and 0.03 mg/kg/min midazolam). The arterial cannula containing 0.9% saline with heparin (50 U/ml) was connected to a pressure transducer (Type 156PC, Honeywell Biomedical Division, Zü rich, Switzerland). Systolic and diastolic BP (SBP/DBP) were allowed to stabilise for 45 min before continuous recording for 15 min using a W & W 404 recorder (Kontron Electronic Group, Zü rich, Switzerland). Heart rate was derived from the BP trace. Mean values for SBP and DBP were derived by averaging the values obtained at 3-min intervals. MAP was calculated as diastolic + 1/3 pulse pressure.
Rats were killed with sodium pentobarbitone (200 mg/kg i.v.). The atria, a section of left quadriceps muscle, left kidney, spleen, mesenteric vasculature and adrenal glands were immediately removed, weighed, frozen on dry ice, and stored at −70°C until extraction. Frozen tissues were homogenized on ice in 50 mM HCl containing 500 nM 3,4-dihydroxybenzylamine, 5 mg/l ascorbic acid and 20 mg/l disodium EDTA. A sample of each homogenate was then diluted with an equal volume of 0.8 M perchloric acid containing 5 mg/l ascorbic acid to precipitate proteins prior to catecholamine measurements. Noradrenaline (NA) and adrenaline were determined by HPLC with electrochemical detection. 10 NPY levels in tissue extracts were measured by immunoradiometric assay.
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Results shown as means ± s.e.m. were compared by analysis of variance. No significant differences were observed in the BP values between the salineminipump and untreated rats of the respective strains (Table 1) . Therefore, tissue values for each strain in these groups were combined to produce a control normotensive rat (NR) group and a control SHR group. Tissue values for NPY and NA were compared by two-way analysis of variance for strain and lisinopril-induced differences. Individual group comparisons for the different strains were made using Student's t-test for unpaired data. 
Results
Lisinopril significantly lowered SBP, DBP and MAP in both rat strains (Table 1) , but did not alter heart rate. Following treatment of SHR with lisinopril, SBP remained significantly higher than untreated NR (P Ͻ 0.05), but MAP was not significantly different from untreated NR, demonstrating the effectiveness of the dose employed. Strain differences in tissue levels of NPY were observed in the atria, kidney and spleen-namely, compared to NR, NPY levels in SHR were lower by 33% in the atria (P Ͻ 0.001), 32% in the kidney (P Ͻ 0.01), and 52% in the spleen (P Ͻ 0.01) ( Figure  1 ). Two-way ANOVA showed lisinopril significantly increased NPY levels in the atria (P = 0.03) and skeletal muscle (P = 0.02). Compared to the corresponding control groups, NPY levels were significantly increased in extracts of atria (+15%, P Ͻ 0.05) and muscle (+70%, P Ͻ 0.05) from SHR, and kidney (+52%, P Ͻ 0.05) from NR.
Strain differences in NA content of extracts from SHR, compared to NR, were observed in skeletal muscle (−13%, P = 0.04), kidney (−14%, P = 0.03), and spleen (−62%, P Ͻ 0.001). Compared to the corresponding control group, treatment with lisinopril only induced a significant change in NA levels in the atrial extracts from SHR (+16%, P Ͻ 0.05).
Adrenal weight expressed as a function of body weight (mg adrenal/100 g) was significantly lower in SHR (19.2 ± 0.2 vs 24.0 ± 0.7). Expressed as total adrenal content NPY and noradrenaline levels were significantly lower in SHR (2.8 ± 0.1 vs 6.1 ± 0.3 pmol NPY/adrenal, P Ͻ 0.001; 17.5 ± 0.5 vs 29.6 ± 1.0 nmol NA/adrenal, P Ͻ 0.001). Total adrenaline content was not different (SHR 74.2 ± 2.6 vs 84.7 ± 3.9 nmol adrenaline/adrenal). Treatment with lisinopril did not affect the adrenal content of NPY, NA or adrenaline in either strain.
Discussion
These results provide further evidence for AII as an important factor in the homeostatic regulation of BP even under basal conditions in normotensive animals. Pressor responses to NA in SHR are similar to those of control rats, but neurogenic vasoconstrictor responses are greater in SHR. 12 Interestingly, ACE inhibition produces a greater attenuation of nerve stimulated responses in SHR compared to control. 12 Acutely, inhibition of AII formation may alter the release of sympathetic neurotransmitters or may have a direct action on effector cell-responsiveness. [3] [4] [5] [6] With chronic ACE inhibition transmitter synthesis may be altered or other actions resulting in structural changes in the vasculature may occur. [3] [4] [5] [6] NPY is located primarily in sympathetic nerve fibres surrounding small arteries where it probably plays a role in the regulation of vascular resistance. Tissue levels of NPY were lower in extracts of atria and skeletal muscle from SHR, but treatment with lisinopril significantly increased NPY content of these tissues. Although, little information can be derived about turnover of NPY from the measurement of tissue levels, these increased levels are compatible with a decrease in sympathetic nerve activity. This is consistent with the hypothesis that ACE inhibition blocks a physiological AII-dependent facilitation of sympathetic transmitter release. Interestingly, treatment of hypertension in transgenic rats overexpressing the mouse renin gene by either ACE-inhibition or AT 1 receptor antagonist also results in an increase in cardiac NPY levels. 13 Conversely, during the development of DOCA-salt Journal of Human Hypertension hypertension NPY levels decrease in tissue and increase in plasma, 14 and repeated behavioural stress combined with high salt diet also causes marked increase in plasma NPY levels. 15 In conclusion, NPY appears to be a useful indicator of sympathetic function in hypertension as treatments which prevent the actions of AII lower BP and reduce the release of NPY.
